Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data

Vaccine

Volumn 33, Issue 48, 2015, Pages 6710-6718

  Galactionova, Katya ^a,b   Bertram, Melanie ^c   Lauer, Jeremy ^c   Tediosi, Fabrizio ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Costing; Malaria; RTS,S; Vaccine; Vaccine introduction

Indexed keywords

MALARIA VACCINE; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ARTICLE; BURKINA FASO; COHORT ANALYSIS; ECONOMIC EVALUATION; GEOGRAPHIC DISTRIBUTION; GHANA; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; IMMUNIZATION; INFANT; KENYA; MALARIA; PRIORITY JOURNAL; SENEGAL; TANZANIA; UGANDA; AFRICA; COST; ECONOMICS;

AFRICA; COSTS AND COST ANALYSIS; HUMANS; IMMUNIZATION; INFANT; MALARIA; MALARIA VACCINES; VACCINES, SYNTHETIC;

EID: 84949894909     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.079     Document Type: Article

References (35)

1. Ballou R.W. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol 2009, 31(9):492-500.
2. The RTS SCTP Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PloS Med 2014, 11(7):e1001685.
3. The RTS SCTP Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomized, controlled trial. Lancet 2015.
4. Immunization VaB, WHO Questions and answers on malaria vaccines 2014, World Health Organization.
5. Penny M., Galactionova K., Tarantino M., Tanner M., Smith T. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using Phase III data and simulation models. BMC Med 2015, 13(170.).
6. Moorthy V.S., Hutubessy R., Newman R.D., Hombach J. Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses. Bull World Health Organ 2012, 90:864-866.
7. Walker D.G., Hutubessy R., Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28(March (11)):2356-2359.
8. Makinen M., Kaddar M., Molldrem V., Wilson L. New vaccine adoption in lower-middle-income countries. Health Policy Plan 2012, 27.
9. Brooks A., Nunes J.K., Garnett A., et al. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Global Public Health 2012, 7(July (9)):931-945.
10. Malaria Vaccine Initiative, PATH Public-sector preferences for RTS,S/AS01 malaria vaccine formulation, presentation, and packaging 2008, PATH MVI.
11. The RTS SCTP A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(November (24)):2284-2295.
12. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford, United Kingdom. 3rd ed.
13. World Health Organization Guidelines for estimating costs of introducing new vaccines into the National Immunization System 2002, WHO, Geneva, Report No.: WHO/V&B/02.11.
14. Expanded Program on Immunization of the Department of Immunization VaB Immunization in practice: a practical guide for health staff 2004, May, World Health Organization, Geneva, Report No.: WHO/IVB/04/06.
15. US Agency for International Development Immunization basics 2005.
16. US Agency for International Development Immunization essentials: a practical field guide 2003.
17. Children's Vaccine Program at PATH Guidelines for implementing supportive supervision: a step-by-step guide with tools to support immunization 2003, PATH, Seattle.
18. Bill and Melinda Gates Children's Vaccine Program at PATH Advocacy for immunization. How to generate and maintain support for vaccination programs 2001.
19. Hutton G., Tediosi F. The costs of introducing a malaria vaccine through the Expanded Program on Immunization in Tanzania. Am J Trop Med Hygine 2006, 75(Suppl. 2):119-130.
20. Griffiths U.K., Korczak V.S., Ayalew D., Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2009, 27:1426-1432.
21. Hutubessy R., Levin A., Wang S., et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Med 2012, 10:136.
22. Edmunds W.J., Dejene A., Mekonnen Y., Haile M., Alemnu W., Nokes D.J. The cost of integrating hepatitis B virus into national immunization programmes: a case study from Addis Ababa. Health Policy Plan 2000, 15(4):408-416.
23. Levin C.E., Minh H.V., Odaga J., et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ 2013, 91:585-592.
24. Ministry of Health and Social Welfare-Tanzania Mainland. Expanded Program on Immunization 2011-2015 comprehensive multi-year plan 2011.
25. Ministry of Health Ghana Immunization programme comprehensive multi-year plan (2010-2014) 2010.
26. Uganda National Expanded Programme on Immunization Uganda National Expanded Programme on Immunization Multi Year Plan 2012-2016 2012.
27. Directorate of Prevention through Immunization Complete multiyear plan for the expanded programme of immunization (cMYP-EPI). Years 2006-2010 2006, Ministry of Health Burkina Faso.
28. Division ofVaccines and Immunization (DVI) Kenya DVI comprehensive multi-year plan 2011-2015 2011, Ministry Health and Sanitation of Republic of Kenya.
29. Department of Medical Prevention EPI comprehensive multiyear plan 2012-2016 2012, Ministry of Public Health and Prevention of Republic of Senegal.
30. United Nations Children's Fund UNICEF supply catalogue 2012, UNICEF, 26-3-2014.
31. WHO-Choice Tables of costs and prices used in WHO-CHOICE analysis 2011, World Health Organization.
32. Pelliser J.M., Copland P.M., Jackson L.A., May J.E. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care 2000, 6(9):1038-1044.
33. De la Hoz-Restrepo F., Castaeda-Orjuela C., Paternina A., Alvis-Guzman N. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines. Vaccine 2013, 31(Suppl. 3):C80-C87.
34. Klinger C., Thoumi A.I., Mrithinjayam V.S. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine 2012, 31:252-259.
35. Gavi The Vaccine Alliance Vaccine introduction grants and operational support for campaigns policy 2015.